Innoviva, Inc. Common Stock INVA
i
Market dataready · fetched 2026-11-06T21:38:29.037Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:26.123112417Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-06T21:38:28.543100+00:00
Innoviva, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.29 | 156.3% | 21.5% | |||
| 25Δ | 21.27 | 64.0% | 13.0% | 16.74 | 181.9% | 21.4% |
| 30Δ | 20.52 | 54.4% | 9.3% | 17.18 | 207.6% | 21.3% |
| 35Δ | 19.89 | 50.7% | 6.6% | 17.69 | 218.9% | 20.2% |
| 40Δ | 19.54 | 60.4% | 6.4% | 18.38 | 192.7% | 16.6% |
| 45Δ | 19.19 | 70.0% | 6.2% | 19.06 | 166.4% | 13.0% |
| 50Δ | 18.84 | 79.6% | 6.0% | 19.75 | 140.2% | 9.4% |
| 55Δ | 18.50 | 89.2% | 5.8% | |||
| 60Δ | 18.15 | 98.8% | 5.6% | |||
| 65Δ | 17.80 | 108.4% | 5.4% | |||
| 70Δ | 17.39 | 117.2% | 5.1% | |||
| 75Δ | 16.66 | 120.7% | 4.2% | |||
| 80Δ | 15.92 | 124.3% | 3.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.29
- IV
- 156.3%
- B/E move
- 21.5%
25Δ
- Pseudo strike
- 21.27
- IV
- 64.0%
- B/E move
- 13.0%
- Pseudo strike
- 16.74
- IV
- 181.9%
- B/E move
- 21.4%
30Δ
- Pseudo strike
- 20.52
- IV
- 54.4%
- B/E move
- 9.3%
- Pseudo strike
- 17.18
- IV
- 207.6%
- B/E move
- 21.3%
35Δ
- Pseudo strike
- 19.89
- IV
- 50.7%
- B/E move
- 6.6%
- Pseudo strike
- 17.69
- IV
- 218.9%
- B/E move
- 20.2%
40Δ
- Pseudo strike
- 19.54
- IV
- 60.4%
- B/E move
- 6.4%
- Pseudo strike
- 18.38
- IV
- 192.7%
- B/E move
- 16.6%
45Δ
- Pseudo strike
- 19.19
- IV
- 70.0%
- B/E move
- 6.2%
- Pseudo strike
- 19.06
- IV
- 166.4%
- B/E move
- 13.0%
50Δ
- Pseudo strike
- 18.84
- IV
- 79.6%
- B/E move
- 6.0%
- Pseudo strike
- 19.75
- IV
- 140.2%
- B/E move
- 9.4%
55Δ
- Pseudo strike
- 18.50
- IV
- 89.2%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 18.15
- IV
- 98.8%
- B/E move
- 5.6%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 17.80
- IV
- 108.4%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 17.39
- IV
- 117.2%
- B/E move
- 5.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 16.66
- IV
- 120.7%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 15.92
- IV
- 124.3%
- B/E move
- 3.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 73.66% | |
| 101.97% | |
| 43.64% | |
| 68.47% | |
| 62.08% | |
| 86.39% | |
| 114.02% | |
| 126.22% | |
| 42.18% | |
| 46.09% | |
| 54.65% | |
| 56.68% | |
| 49.97% | |
| 61.66% | |
| 58.45% | |
| 54.22% | |
| 129.28% | |
| 100.34% | |
| 103.16% | |
| 43.93% | |
| 36.23% | |
| 64.11% | |
| 55.70% | |
| 48.62% | |
| 50.50% | |
| 60.39% | |
| 70.93% | |
| 49.91% | |
| 61.42% |
Biotechnology
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge…
More →IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious…
More →IVA
Description unavailable
More →